Recommended Topic Related To:

Zingo

"Oct. 19, 2012 -- Today's parents may need to update their advice for crossing the street safely to: “Look both ways and turn off the cell phone!”

A new study shows teens are twice as likely as adults to be hit by a car while crossing"...

Zingo

Indications
Dosage
How Supplied

INDICATIONS

Zingo™ (lindocaine hydrochloride monohydrate) is indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3–18 years of age.

Zingo™ (lindocaine hydrochloride monohydrate) is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults.

DOSAGE AND ADMINISTRATION

Apply one Zingo™ (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion.

Perform the procedure within 10 minutes after Zingo™ (lindocaine hydrochloride monohydrate) administration.

Use Zingo™ (lindocaine hydrochloride monohydrate) only on intact skin.

Application of one additional Zingo™ (lindocaine hydrochloride monohydrate) at a new location is acceptable after a failed attempt at venous access. Multiple administrations of Zingo™ (lindocaine hydrochloride monohydrate) at the same location are not recommended.

When Zingo™ (lindocaine hydrochloride monohydrate) is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all sources should be considered, as local anesthetics are thought to have at least additive toxicities.

Instructions for Use

Prepare the Treatment Site and Device: Examine the treatment site to ensure that the skin is intact. Clean the site, according to standard practice.

Visually inspect the pouch. Do not use if the pouch has been torn, or damaged or if the device has been dropped.

Tear open the pouch using the notch provided (Figure 1a). Remove Zingo™ (lindocaine hydrochloride monohydrate) from the pouch, being careful not to touch the purple outlet (open end) to avoid contamination. (Figure 1b).

Figure 1a

Tear open the pouch using the notch provided -  Illustration

Figure 1b

Avoid contamination - Illustration

Position Zingo™ (lindocaine hydrochloride monohydrate) : Grip Zingo™ (lindocaine hydrochloride monohydrate) and place on the application site, with one hand, as illustrated in Figure 2, or with both hands, as shown in Figure 3.

Figure 2

Position Zingo - Illustration

Figure 3

Position Zingo - Illustration 2

Ensure that the patient's treatment site is supported to prevent movement. Seal the purple Zingo™ (lindocaine hydrochloride monohydrate) outlet against the patient's skin. Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.

Avoid gaps between the skin and the Zingo™ (lindocaine hydrochloride monohydrate) outlet, like the one illustrated in Figure 4, as gaps will impede drug delivery.

Figure 4

Avoid gaps between the skin and the Zingo - Illustration

Release the Safety Interlock: Apply adequate downward pressure to release the safety interlock, while maintaining the seal between Zingo™ (lindocaine hydrochloride monohydrate) and the skin.

Zingo™ (lindocaine hydrochloride monohydrate) is ready for administration when the green start button has moved into the upward position, as illustrated in Figure 5a.

Figure 5a

Ready for administration - Illustration

Zingo™ (lindocaine hydrochloride monohydrate) cannot be actuated without releasing the internal safety interlock, as illustrated in Figure 5b.

Figure 5b

Zingo cannot be actuated without releasing the internal safety interlock - Illustration

Administer Zingo™ (lindocaine hydrochloride monohydrate) : While maintaining downward pressure, administer the dose by pressing the green start button, as illustrated in Figure 6. Do not move Zingo™ (lindocaine hydrochloride monohydrate) during administration. Actuation is accompanied by a “popping” sound, indicating that the dose has been discharged.

Figure 6

Push button inward - Illustration

Remove Zingo™ (lindocaine hydrochloride monohydrate) : Remove Zingo™ (lindocaine hydrochloride monohydrate) from the application site and dispose.

Begin Procedure: Start the venipuncture or intravenous cannulation procedure 1–3 minutes after Zingo™ (lindocaine hydrochloride monohydrate) administration.

HOW SUPPLIED

Dosage Forms And Strengths

Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile lidocaine hydrochloride monohydrate.

NDC 28000-105-12 Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile lidocaine hydrochloride monohydrate. Zingo™ (lindocaine hydrochloride monohydrate) is a single-use device packaged in an individual foil/clear pouch placed inside a bubble-wrap sleeve. Twelve sleeves are placed in labeled cartons.

Cartons are stored at controlled room temperature (15-30°C, 59-86°F).

Manufactured for: Anesiva, Inc. South San Francisco, CA 94080. Distributed by: Sagent Pharmaceuticals, Inc. Schaumburg, IL 60195.

Last reviewed on RxList: 2/27/2009
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Parenting and Pregnancy

Get tips for baby and you.


NIH talks about Ebola on WebMD